

## Special Issue

# Therapeutic Targets and Personalized Medicine in Cardiac Disease

### Message from the Guest Editors

Cardiovascular disease has been the subject of extensive research and notable advancements over decades. However, it remains the leading cause of death, with millions affected worldwide. The available therapeutic options leave a lot to be desired in many cases, while they remain non-existent in others. Importantly, there are many cases where prognosis is challenging and response to treatment highly variable. Even when the cause has a genetic basis, different mutations within the same gene can result in different pathophysiology, while the same gene mutation can lead to variable phenotypes. The remarkable technological advancements and scientific breakthroughs over recent years are unveiling a horizon of new possibilities. This Special Issue focuses on cutting-edge developments in the discovery of novel CVD targets and the development of personalized therapeutic approaches. We invite the submission of original research and review articles on the latest scientific advances toward understanding and combating CVD in the Precision Medicine era. Dr. Irene C. Turnbull

---

### Guest Editors

Dr. Elizabeth Vafiadaki

Dr. Despina Sanoudou

Dr. Irene Turnbull

---

### Deadline for manuscript submissions

closed (30 November 2022)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/si/74414](https://mdpi.com/si/74414)

*Journal of Personalized  
Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 4.1  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).